ligelizumab   Click here for help

GtoPdb Ligand ID: 8997

Synonyms: CL-2C | NVP-QGE031 | QGE031
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ligelizumab is a humanized, investigational high-affinity anti-IgE monoclonal antibody with anti-inflammatory potential [1], with improved pharmacokinetics and clinical effects compared to omalizumab.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches with antibody sequences claimed in patent US7531169 B2, where it is the clone designated as CL-2C [3].
Click here for help
1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Clin Exp Allergy, 44 (11): 1371-85. [PMID:25200415]
2. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE et al.. (2011)
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.
Allergy, 66 (3): 317-30. [PMID:21083565]
3. Singh S, Foster C, Wu H. (2009)
High affinity anti-human IgE antibodies.
Patent number: US7531169 B2. Assignee: Tanox, Inc.. Priority date: 01/02/2003. Publication date: 12/05/2009.
4. Trischler J, Bottoli I, Janocha R, Heusser C, Jaumont X, Lowe P, Gautier A, Pethe A, Woessner R, Zerwes HG et al.. (2021)
Ligelizumab treatment for severe asthma: learnings from the clinical development programme.
Clin Transl Immunology, 10 (3): e1255. [PMID:33747510]